A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for theTreatment of Unresectable and Metastatic Conventional Chondrosarcoma
Study of Belinostat and Guadecitabine for Treatment of Chondrosarcoma
Sponsor: National Cancer Institute
Enrolling: Male and Female Patients
IRB Number: AAAT2009
U.S. Govt. ID: NCT04340843
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This study is being done to answer the following question: Is the combination of the drugs belinostat and SGI-110 (guadecitabine) effective at lowering the chance of your chondrosarcoma growing or spreading?
Investigator
Matthew Ingham, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with chondrosarcoma that cannot be removed by surgery? Yes No
Are you able to come to the clinic for 5 consecutive days each month to get treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162